KisoJi Biotechnology Snapshot
KisoJi is a leading next-generation antibody company discovering and developing highly differentiated antibody therapeutics to address difficult targets in oncology and other diseases. Our antibody platform enables the visualization of the complete immune response of an animal, allowing unprecedented direct control over antibody sampling for therapeutic, diagnostic, and vaccine development. The platform is built upon single domain antibodies from KisoJi’s proprietary multi-species single domain antibody transgenic mice, an AI-enabled antibody fingerprinting technology and the ability to create robust, easily manufacturable multi-specific antibodies.
Experienced and successful team of antibody scientists with deep expertise in antibody development and a demonstrated track record of innovation.
Lead program: a novel TROP2 antibody with robust therapeutic activity without the need for a drug conjugate.
Proprietary antibody development platform to create the next generation of antibody drugs.
KisoJi antibody platform was developed entirely in-house, leveraging decades of antibody discovery and development experience. This platform transforms how we think of antibody discovery and enables KisoJi to uncover novel biology on targets in order to develop radically new antibody therapeutics. From this platform, the Company has developed a preclinical pipeline that includes tri-specific immune-oncology antibodies for both solid and hematologic cancers, as well as potent novel antibodies superior to ADCs.
KisoMouse
Multi-species transgenic mouse platform for single domain antibody production with picomolar affinity and the most diverse immune response.
KisoSeek
AI-driven structural antibody screening that can sort through millions of antibodies at a time.
KisoBody
A powerfully simple, multi-functional and multi-specific antibody format designed to enhance efficacy and safety by targeting multiple antigens or epitopes simultaneously.